ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Forest Labs Will Acquire Furiex

by Ann M. Thayer
May 5, 2014 | APPEARED IN VOLUME 92, ISSUE 18

Forest Laboratories will pay up to $1.5 billion to purchase Furiex Pharmaceuticals of Morrisville, N.C. Furiex expects to apply soon for FDA approval for its lead product, eluxadoline, a treatment for irritable bowel syndrome. Forest has agreed to sell Furiex’s royalties on two other drugs to Royalty Pharma for $415 million, provided the deal goes through. Forest expanded its gastroenterology business earlier this year by acquiring the specialty pharma firm Aptalis for $2.9 billion. Meanwhile, the generic drug maker Actavis is in the process of acquiring Forest for $25 billion.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment